Cogent surges on trial win for blood disorder drug
ReutersJul 7, 2025 12:03 PM
Shares of drug developer Cogent Biosciences COGT.O rise 19.4% to $9.05 premarket
Co says its drug, bezuclastinib, showed a statistically significant reduction in symptoms in patients with mastocytosis, a type of blood disorder
Mastocytosis is a disease where the body makes too many of a type of white blood cell called mast cells, which build up in places like the bone marrow, skin or organs
COGT expects to file a marketing application for the treatment by the end of 2025
Up to last close, stock down 2.8% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Eurozone Inflation Gradually Recedes Will ECB Rate-Cut Window Open Again? 2026 Euro Exchange Rate Trend Forecast
TradingKey - After enduring three consecutive years of "high prices, high interest rates, high debt, and low growth," the Eurozone economy is finally demonstrating resilience through a moderate recovery. Currently, the European Central Bank (ECB) faces the ultimate test of maintaining the status quo versus implementing "preemptive rate cuts." Euro exchange rate volatility, inflation trends, and the economic outlook have become the primary focus for investors and financial enthusiasts when allocating overseas assets and capitalizing on currency opportunities.TradingKey
9 hours ago
AMD Stock Price Prediction 2030: Can AMD Narrow Nvidia’s AI Lead?
TradingKey - In the past couple of years, the semiconductor industry has experienced a major change. One question that investors still have is whether or not AMD (AMD) will be able to keep up with Nvidia (NVDA) as far as AI is concerned. What is the possible future of AMD's stock through 2026 and beTradingKey
14 hours ago
Bitcoin Price Prediction 2029-2035: Institutional Accumulation and the U.S. Treasury’s Strategic Reserve Pivot
Explore the 2026 Bitcoin landscape: From the U.S. Strategic Reserve and Michael Saylor’s $75B war chest to Cathie Wood’s 2030 forecast. Is BTC the new Digital Gold?TradingKey
Fri, Feb 13
